Teva Canada Welcomes Public Drug Plan Reimbursement by Alberta, Saskatchewan, Québec, Veteran Affairs Canada and the Non-Insured Health Benefits Program for Patients prescribed AJOVY® (fremanezumab) for the Preventive Treatment of Migraine in Adults
Public formulary and program coverage makes AJOVY® accessible to more migraine patients across Canada MONTRÉAL--(BUSINESS WIRE)--Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., welcomes the recently announced public formulary